PTC Therapeutics Inc MOVE-FA Topline Results-Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : So when I look at Slide 11, and this is also in your prepared remarks, it looks like the benefit from week 60 to 72 is perhaps where you're seeing the most robust trends. So I'm curious if you can comment on the open-label extension study enrollment to understand if you're looking at the effects between the 2 arms longer term beyond week 72. And if that is the case, how much data could you potentially have to bring to the FDA and the EMA when you intend to meet?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Great. And then last question is just on that note, when you look at the different subscales in the primary endpoint analysis like bulbar function and upper limb benefits where you saw some clear benefits, I'm curious over time if that tends to happen with these patients. I know we don't have a lot of like treatment experience but just even like from a natural history, like if typically, these patients would benefit on all at once? Or is there really kind of like a natural progression that perhaps some of these endpoints become more clear with intervention over time or even just slowing down when you're not on any treatment?